Lymphoma, T-Cell clinical trials
The registry lists 310 studies for Lymphoma, T-Cell across more than 10 countries. 78 are recruiting or about to start. 138 of them are mainly about Lymphoma, T-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 7 narrower conditions too, such as Lymphoma, T-Cell, Cutaneous: 1,397 studies, 275 open.
Get an email when these change. Save the Lymphoma, T-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (21) · M.D. Anderson Cancer Center (17) · Sun Yat-sen University (11) · City of Hope Medical Center (8) · Memorial Sloan Kettering Cancer Center (8) · Mayo Clinic (7) · Ruijin Hospital (6) · Fred Hutchinson Cancer Center (6)
What is being tested here
Drugs under test in Lymphoma, T-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cyclophosphamide | 3 | 0 | 9 |
| Azacitidine | 3 | 1 | 6 |
| Ruxolitinib | 3 | 0 | 5 |
| Tucidinostat | 3 | 2 | 4 |
| Pralatrexate | 2 | 2 | 10 |
| Fludarabine | 2 | 0 | 9 |
| Duvelisib | 2 | 0 | 6 |
| Cemiplimab | 2 | 0 | 2 |
| Brentuximab Vedotin | 1 | 1 | 12 |
| Melphalan | 1 | 0 | 8 |
Drug classes tested here Antimetabolites 9 open · Tyrosine kinase inhibitors (TKIs) 8 open · Alkylating agents 5 open · JAK inhibitors 5 open · Immune checkpoint inhibitors 4 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma · Phase 3 · Ruijin Hospital
- Nov 2027Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · Phase 3 · Corvus Pharmaceuticals, Inc.
- Nov 2026Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma · Yale University
- Nov 2026CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas · Beijing GoBroad Hospital
- Nov 2026JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas · Step Pharma, SAS
- Dec 2026Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) · Sun Yat-sen University
- Dec 2026Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · Children's Hospital Medical Center, Cincinnati
- Dec 2026A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma · Corvus Pharmaceuticals, Inc.
- Dec 2026Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma · Fudan University
Who these studies take
Of the 68 Lymphoma, T-Cell studies recruiting now, 41 (60%) set no upper age limit and 21 (31%) stop at 75 or younger. 15 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (3%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 10 (15%) | 10 (15%) |
| 18 | 65 (96%) | 65 (96%) |
| 30 | 65 (96%) | 65 (96%) |
| 40 | 64 (94%) | 64 (94%) |
| 50 | 64 (94%) | 64 (94%) |
| 65 | 64 (94%) | 64 (94%) |
| 75 | 56 (82%) | 56 (82%) |
| 85 | 45 (66%) | 45 (66%) |
Across all 310 studies, recruiting or not: 27% stop at 75 or younger and 9% at 65; 15% take children; <1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Lymphoma, T-Cell studies take
Of 66 phase 2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 68 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 57 mo26–99 · 59 studies | — | 52 mo26–75 · 40 studies |
| Phase 1/2 | 62 mo49–92 · 29 studies | — | — |
| Phase 2 | 68 mo33–99 · 66 studies | — | 68 mo33–110 · 56 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 50 of 310. Browse all 310 → or search them.
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 11 country
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingNCT07278856Phase 11 country
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 21 country
- Tissue Repository: CTCL Collection ProtocolRecruitingNCT028407471 country
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 21 country
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaRecruitingNCT07691450Phase 11 country
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT061318011 country
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 21 country
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)RecruitingNCT07496229Phase 1/21 country
- Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingNCT07293403Phase 21 country
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 11 country
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingNCT06561048Phase 33 countries
- Long-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsEnrolling by invitationNCT03628612Phase 23 countries
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)RecruitingNCT04752826Phase 1/27 countries
- Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyRecruitingNCT06724237Phase 32 countries
- CD5 CAR T-Cell Therapy for r/r T-cell LymphomasRecruitingNCT07022964Phase 1/21 country
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLRecruitingNCT06854653Phase 24 countries
- A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 11 country
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/27 countries
- Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell NeoplasmsRecruitingNCT07382817Phase 11 country
- CD45BE-HSPC + CART-45 CellsRecruitingNCT07451054Phase 11 country
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 21 country
- Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)RecruitingNCT077508861 country
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/21 country
- Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell MalignanciesRecruitingNCT06699771Phase 11 country
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or LymphomaRecruitingNCT06934382Phase 11 country
- Evaluation of Human Immune Responses Vaccination in Patients With LymphomaRecruitingNCT035015761 country
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 21 country
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 11 country
- CD4CAR for CD4+ Leukemia and LymphomaRecruitingNCT03829540Phase 11 country
- A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.Not yet recruitingNCT07657572
- A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell LymphomasRecruitingNCT05463263Phase 1/23 countries
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 21 country
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 11 country
- A Registry for People With T-cell LymphomaRecruitingNCT059781411 country
- Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin LymphomaRecruitingNCT07225985Phase 1/21 country
- Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHLRecruitingNCT06874946Phase 1/21 country
- CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid LeukemiaRecruitingNCT06696846Phase 11 country
- Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCLNot yet recruitingNCT07409168
- Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.Not yet recruitingNCT075389601 country
- A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)RecruitingNCT05984147Phase 11 country
- Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06583083Phase 21 country
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaRecruitingNCT05996185Phase 21 country
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell LymphomaRecruitingNCT06314334Phase 21 country
- Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort StudyRecruitingNCT072708611 country
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingNCT07380984Phase 21 country
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingNCT07339527Phase 1/2
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasRecruitingNCT06716658Phase 21 country
- CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT06420089Phase 11 country
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 11 country